How to Take IDVYNSO

Once-daily IDVYNSO helps keep you undetectable with 2 medicines in just 1 pill

IDVYNSO is a once-daily pill you can take with or without food at about the same time every day

Always take IDVYNSO exactly as your healthcare provider tells you to. It is important to not miss or skip a dose.

IDVYNSO is taken by itself (without other HIV-1 medicines)

If you take the medicine rifabutin during treatment with IDVYNSO, your healthcare provider will also prescribe an additional dose of doravirine to make sure you have enough doravirine (one of the medicines in IDVYNSO) in your blood when taking these medicines together. Carefully follow your healthcare provider’s instructions about when to take doravirine and how much to take. This is usually 1 tablet of doravirine about 12 hours after your dose of IDVYNSO.

If you miss a dose?

If you forget to take IDVYNSO every day at a regularly scheduled time, take the missed dose as soon as you remember. However, if it’s almost time for your next dose, skip the missed dose and take the next dose at your regular time. Do not take 2 doses at the same time. If you have any questions, call your healthcare provider or pharmacist.

If you take too much IDVYNSO, call your healthcare provider or go to the nearest hospital emergency room right away.

If you’re running out?

When your supply of IDVYNSO starts to run low, get more from your healthcare provider or pharmacy. This is very important because the amount of virus in your blood may increase if the medicine is stopped for even a short time. The virus may develop resistance to IDVYNSO and become harder to treat.

It’s important to talk with your healthcare provider before stopping IDVYNSO or changing your dose. Stay under a healthcare provider’s care when taking IDVYNSO.

IDVYNSO can be taken with many prescription and over-the-counter medicines*

  • Hepatitis C antivirals (elbasvir, grazoprevir, ledipasvir, and sofosbuvir)†
  • GERD (pantoprazole)
  • Seizures (midazolam)†
  • Antifungal (ketoconazole)†
  • Antacids (containing aluminum hydroxide/magnesium hydroxide and simethicone)†
  • Oral contraceptives (containing ethinyl estradiol and levonorgestrel)
  • High cholesterol (atorvastatin)
  • Diabetes (metformin)
  • Opioids (methadone)

*Studies showed IDVYNSO and these medications did not affect each other in how they work.

†Taking IDVYNSO with these medications is not expected to change how any of them work because of the way your body processes IDVYNSO.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements, and any new medicines you plan on taking, as some medicines may interact with IDVYNSO.

Do not take IDVYNSO if you take certain medicines that are strong CYP3A inducers, lamivudine, or emtricitabine as they can make IDVYNSO less effective.

These medicines can make IDVYNSO less effective. Ask your healthcare provider or pharmacist if you are not sure if any of your medicines are CYP3A inducers. If you have taken any of these medicines in the past 4 weeks, talk to your healthcare provider or pharmacist before starting treatment with IDVYNSO.

IDVYNSO should not be taken with these medications:

Any drugs that are strong CYP3A enzyme inducers, which may decrease the effectiveness of IDVYNSO

Lamivudine

Emtricitabine

Other HIV medications

Your healthcare provider can tell you if it is safe to take IDVYNSO with other medicines.

Talk to your healthcare provider or pharmacist if you are not sure if any of your medicines are CYP3A inducers. These medicines can make IDVYNSO less effective. If you have taken any of these medicines in the past 4 weeks, talk to your healthcare provider or pharmacist before starting.

Tell your healthcare provider if you have taken rifabutin in the past 4 weeks. If you take IDVYNSO and rifabutin together, your doctor will prescribe additional doravirine, one of the medicines in IDVYNSO.

Before taking IDVYNSO, tell your healthcare provider about all of your medical conditions, including if you:

  • Have liver problems
  • Have ever had hepatitis B virus infection
  • Have kidney problems
  • Are pregnant or plan to become pregnant. It is not known if IDVYNSO can harm your unborn baby. Tell your healthcare provider if you become pregnant during treatment with IDVYNSO.
  • Are breastfeeding or plan to breastfeed. It is not known if IDVYNSO passes into your breast milk. Talk with your healthcare provider about the following risks to your baby from breastfeeding during treatment with IDVYNSO:
    • The HIV-1 virus may pass to your baby if your baby does not have HIV-1.
    • The HIV-1 virus may become harder to treat if your baby has HIV-1.
    • Your baby may get side effects from IDVYNSO.

Make sure your healthcare provider knows about all the medicines and supplements you’re taking

From prescription medicines and over-the-counter supplements to vitamins, it’s important that your healthcare provider knows about everything you’re taking in addition to your HIV treatment. Since IDVYNSO and other medicines can affect how each other work, always keep a list of your treatments to share with your doctor and pharmacist. Always check with your healthcare provider before starting any new medication to ensure it is safe to take with IDVYNSO. Also, tell them if you have taken rifabutin in the past 4 weeks.

What is IDVYNSO?

IDVYNSO is a complete, 1-pill, once-a-day prescription medicine used to treat Human Immunodeficiency Virus-1 (HIV-1) infection in adults. It is used to replace a person’s current HIV-1 medicines for people whose healthcare provider determines that they meet certain requirements.

 

HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome (AIDS). 

IDVYNSO contains the prescription medicines doravirine and islatravir.

Important Safety Information

Do not take IDVYNSO if you take certain medicines that are strong CYP3A inducers, lamivudine, or emtricitabine as they can make IDVYNSO less effective.

 

Talk to your healthcare provider or pharmacist if you are not sure if any of your medicines are CYP3A inducers. If you have taken any of these medicines in the past 4 weeks, talk to them before starting IDVYNSO.

 

Before taking IDVYNSO, tell your healthcare provider about all of your medical conditions, including if you:

  • Have liver or kidney problems, or ever had hepatitis B virus infection.
  • Are pregnant or plan to become pregnant. It is not known if IDVYNSO can harm your unborn baby. Tell them if you become pregnant while taking IDVYNSO.
  • Are breastfeeding (nursing) or plan to breastfeed. It is not known if IDVYNSO passes into your breast milk. Talk with your healthcare provider about the following risks to your baby from breastfeeding during treatment with IDVYNSO: The HIV-1 virus may pass to your baby if your baby does not have HIV-1 infection, the HIV-1 virus may become harder to treat if your baby has HIV-1 infection, and your baby may get side effects from IDVYNSO.
  • Take medicines in addition to your HIV medicine. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
    • Some medicines interact with IDVYNSO. Keep a list of your medicines to show your healthcare provider and pharmacist. You can also ask your healthcare provider for a list of medicines that interact with IDVYNSO.
    • Tell your healthcare provider if you have taken rifabutin in the past 4 weeks.
    • Do not start taking a new medicine without telling your healthcare provider. Your healthcare provider can tell you if it is safe to take IDVYNSO with other medicines.

 

What are the possible side effects of IDVYNSO?

 

IDVYNSO may cause serious side effects, including:

 

Severe skin reactions. Call your healthcare provider right away if you develop a rash during treatment with IDVYNSO. Stop taking IDVYNSO and get medical help right away if you develop a painful rash with any of the following symptoms: fever, blisters or sores in the mouth, blisters or peeling of the skin, swelling of the face or lymph nodes, feeling tired or generally ill, or redness or swelling of the eyes (conjunctivitis).

 

The most common side effects of IDVYNSO include: diarrhea, dizziness, tiredness, stomach (abdominal) bloating, headache and weight gain.

 

These are not all of the possible side effects of IDVYNSO. Call your doctor for medical advice about side effects.

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

 

Please read the accompanying Patient Information for IDVYNSO and discuss it with your healthcare provider. The physician Prescribing Information also is available.

 

What is IDVYNSO?
Important Safety Information

IDVYNSO is a complete, 1-pill, once-a-day prescription medicine used to treat Human Immunodeficiency Virus-1 (HIV-1) infection in adults. It is used to replace a person’s current HIV-1 medicines for people whose healthcare provider determines that they meet certain requirements.

 

HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome (AIDS). 

IDVYNSO contains the prescription medicines doravirine and islatravir.

Important Safety Information

Do not take IDVYNSO if you take certain medicines that are strong CYP3A inducers, lamivudine, or emtricitabine as they can make IDVYNSO less effective.

 

Talk to your healthcare provider or pharmacist if you are not sure if any of your medicines are CYP3A inducers. If you have taken any of these medicines in the past 4 weeks, talk to them before starting IDVYNSO.

 

Before taking IDVYNSO, tell your healthcare provider about all of your medical conditions, including if you:

  • Have liver or kidney problems, or ever had hepatitis B virus infection.
  • Are pregnant or plan to become pregnant. It is not known if IDVYNSO can harm your unborn baby. Tell them if you become pregnant while taking IDVYNSO.
  • Are breastfeeding (nursing) or plan to breastfeed. It is not known if IDVYNSO passes into your breast milk. Talk with your healthcare provider about the following risks to your baby from breastfeeding during treatment with IDVYNSO: The HIV-1 virus may pass to your baby if your baby does not have HIV-1 infection, the HIV-1 virus may become harder to treat if your baby has HIV-1 infection, and your baby may get side effects from IDVYNSO.
  • Take medicines in addition to your HIV medicine. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
    • Some medicines interact with IDVYNSO. Keep a list of your medicines to show your healthcare provider and pharmacist. You can also ask your healthcare provider for a list of medicines that interact with IDVYNSO.
    • Tell your healthcare provider if you have taken rifabutin in the past 4 weeks.
    • Do not start taking a new medicine without telling your healthcare provider. Your healthcare provider can tell you if it is safe to take IDVYNSO with other medicines.

 

What are the possible side effects of IDVYNSO?

 

IDVYNSO may cause serious side effects, including:

 

Severe skin reactions. Call your healthcare provider right away if you develop a rash during treatment with IDVYNSO. Stop taking IDVYNSO and get medical help right away if you develop a painful rash with any of the following symptoms: fever, blisters or sores in the mouth, blisters or peeling of the skin, swelling of the face or lymph nodes, feeling tired or generally ill, or redness or swelling of the eyes (conjunctivitis).

 

The most common side effects of IDVYNSO include: diarrhea, dizziness, tiredness, stomach (abdominal) bloating, headache and weight gain.

 

These are not all of the possible side effects of IDVYNSO. Call your doctor for medical advice about side effects.

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

 

Please read the accompanying Patient Information for IDVYNSO and discuss it with your healthcare provider. The physician Prescribing Information also is available.